Theravance Biopharma Inc
Closed
16.29 2.45
Overview
Share price change
24h
Min
15.89
Max
16.45
Income | -66M -4.9M |
|---|---|
Sales | -28M 18M |
P/E Sector Avg | 7.148 49.888 |
EPS | 0.01 |
Profit margin | -27.872 |
Employees | 90 |
EBITDA | -26M -6.9M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +7.6% upside |
Next Earnings | 11 Aug 2026 |
|---|
Market Cap | -49M 822M |
|---|---|
Previous open | 13.84 |
Previous close | 16.29 |
Theravance Biopharma Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Theravance Biopharma Inc Forecast
Price Target
By TipRanks
7.6% upside
12 Months Forecast
Average 17.13 USD 7.6%
High 21 USD
Low 13.67 USD
Based on 5 Wall Street analysts offering 12 month price targets forTheravance Biopharma Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
